BIIB
Biogen Inc. NASDAQ Listed Sep 17, 1991$191.46
Mkt Cap $28.3B
52w Low $115.25
87.4% of range
52w High $202.41
50d MA $184.38
200d MA $165.40
P/E (TTM)
21.1x
EV/EBITDA
9.6x
P/B
1.5x
Debt/Equity
0.4x
ROE
9.3%
P/FCF
12.6x
RSI (14)
—
ATR (14)
—
Beta
0.16
50d MA
$184.38
200d MA
$165.40
Avg Volume
1.3M
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; ADUHELM for the treatment of Alzheimer's disease; IMRALDI, an adalimumab biosimilar referencing HUMIRA; and FLIXABI, an infliximab biosimilar referencing REMICADE. In addition, the company offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; and OCREVUS for treating relapsing MS and primary progressive MS; and other anti-CD20 therapies. Further, it develops BIIB135, BIIB061, BIIB091, and BIIB107 for MS and neuroimmunology; Aducanumab, Lecanemab, BIIB076, and BIIB080 to treat Alzheimer's disease and dementia; BIIB067, BIIB078, BIIB105, BIIB100, and BIIB110 to treat neuromuscular disorders; BIIB124, BIIB094, BIIB118, BIIB101, and BIIB122 for treating Parkinson's disease and movement disorders; BIIB125 and BIIB104 for treating neuropsychiatry; Dapirolizumab pegol and BIIB059 to treat immunology related diseases; BIIB093 and BIIB131 to treat acute neurology; BIIB074 for neuropathic pain; and BYOOVIZ, BIIB800, and SB15 biosimilars, which are under various stages of development. The company has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc. Biogen Inc. was founded in 1978 and is headquartered in Cambridge, Massachusetts.
225 Binney Street · Cambridge, MA 02142 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 29, 2026 | TNS | 3.05 | 3.57 | +17.0% | 194.38 | -0.2% | -2.6% | -3.8% | -3.7% | -2.7% | -1.9% | — |
| Feb 6, 2026 | TNS | 1.63 | 1.99 | +22.1% | 201.18 | -0.7% | -3.7% | -6.1% | -5.0% | -2.8% | -2.3% | — |
| Oct 30, 2025 | TNS | 3.88 | 4.81 | +24.0% | 149.61 | -1.1% | +3.1% | +1.2% | -0.2% | +2.6% | +4.8% | — |
| Jul 31, 2025 | TNS | 3.90 | 5.47 | +40.3% | 128.00 | +0.8% | +3.1% | +3.3% | +3.8% | +1.0% | -0.2% | — |
| May 1, 2025 | TNS | 2.90 | 3.02 | +4.1% | 120.93 | +1.2% | +2.1% | +0.7% | -3.4% | -3.1% | -2.1% | — |
| Feb 12, 2025 | TNS | 3.43 | 3.44 | +0.3% | 133.43 | -1.0% | +3.8% | +2.9% | +2.4% | +2.4% | +2.7% | — |
| Oct 30, 2024 | TNS | 3.77 | 4.08 | +8.2% | 181.18 | -1.7% | -4.0% | -4.1% | -4.2% | -2.3% | -3.7% | — |
| Aug 1, 2024 | TNS | 4.07 | 5.28 | +29.7% | 210.70 | +0.8% | -2.4% | -5.8% | -5.0% | -5.2% | -3.1% | — |
| Apr 24, 2024 | TNS | 3.47 | 3.67 | +5.8% | 201.99 | -0.4% | +0.2% | +3.4% | +6.7% | +6.4% | +7.0% | — |
| Feb 13, 2024 | TNS | 3.16 | 2.95 | -6.6% | 226.65 | +0.2% | -2.6% | -1.5% | -3.3% | -3.3% | -2.4% | — |
| Nov 8, 2023 | TNS | 3.99 | 4.36 | +9.3% | 231.69 | +0.1% | -3.0% | -3.0% | -3.9% | -2.8% | -0.9% | — |
| Jul 25, 2023 | TNS | 3.77 | 4.02 | +6.6% | 270.31 | -0.1% | -1.9% | -2.8% | -1.9% | -0.0% | -0.4% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 1 | Citigroup | Maintains | Neutral → Neutral | — | $189.28 | $189.28 | +0.0% | -1.2% | -1.1% | -0.1% | +0.7% | +1.1% |
| Apr 30 | RBC Capital | Maintains | Outperform → Outperform | — | $194.38 | $194.02 | -0.2% | -2.6% | -3.8% | -3.7% | -2.7% | -1.9% |
| Apr 30 | Guggenheim | Maintains | Buy → Buy | — | $194.38 | $194.02 | -0.2% | -2.6% | -3.8% | -3.7% | -2.7% | -1.9% |
| Apr 30 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $194.38 | $194.02 | -0.2% | -2.6% | -3.8% | -3.7% | -2.7% | -1.9% |
| Apr 30 | Wedbush | Maintains | Neutral → Neutral | — | $194.38 | $194.02 | -0.2% | -2.6% | -3.8% | -3.7% | -2.7% | -1.9% |
| Apr 22 | UBS | Upgrade | Neutral → Buy | $225 | $185.95 | $189.31 | +1.8% | +2.2% | +1.0% | -0.8% | -2.8% | -1.4% |
| Apr 20 | Wells Fargo | Upgrade | Equal Weight → Overweight | — | $177.35 | $179.54 | +1.2% | +3.4% | +4.8% | +7.2% | +5.9% | +4.0% |
| Apr 14 | Piper Sandler | Upgrade | Neutral → Overweight | — | $176.37 | $177.71 | +0.8% | +1.5% | +2.4% | -0.2% | +0.6% | +4.0% |
| Apr 13 | Citigroup | Maintains | Neutral → Neutral | — | $172.97 | $172.62 | -0.2% | +2.0% | +3.5% | +4.4% | +1.8% | +2.5% |
| Apr 13 | Truist | Maintains | Hold → Hold | — | $172.97 | $172.62 | -0.2% | +2.0% | +3.5% | +4.4% | +1.8% | +2.5% |
| Apr 10 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $177.11 | $177.97 | +0.5% | -2.3% | -0.4% | +1.0% | +1.9% | -0.6% |
| Apr 2 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $183.78 | $181.46 | -1.3% | -3.5% | -6.2% | -4.4% | -2.1% | -3.6% |
| Apr 1 | Canaccord Genuity | Maintains | Buy → Buy | — | $183.33 | $183.16 | -0.1% | +0.2% | -3.3% | -6.0% | -4.2% | -1.9% |
| Apr 1 | Oppenheimer | Maintains | Outperform → Outperform | — | $183.33 | $183.16 | -0.1% | +0.2% | -3.3% | -6.0% | -4.2% | -1.9% |
| Mar 17 | HSBC | Maintains | Reduce → Reduce | — | $183.26 | $184.73 | +0.8% | +1.1% | -0.5% | +0.1% | -1.0% | +0.2% |
| Feb 23 | Freedom Broker | Maintains | Hold → Hold | — | $192.03 | $191.82 | -0.1% | +2.2% | +1.6% | -0.7% | -2.1% | -0.1% |
| Feb 10 | Wedbush | Maintains | Neutral → Neutral | — | $193.81 | $194.07 | +0.1% | -2.5% | -1.3% | +0.9% | +1.4% | +0.9% |
| Feb 9 | RBC Capital | Maintains | Outperform → Outperform | — | $201.18 | $199.83 | -0.7% | -3.7% | -6.1% | -5.0% | -2.8% | -2.3% |
| Feb 9 | Wedbush | Maintains | Neutral → Neutral | — | $201.18 | $199.83 | -0.7% | -3.7% | -6.1% | -5.0% | -2.8% | -2.3% |
| Feb 9 | JP Morgan | Maintains | Neutral → Neutral | — | $201.18 | $199.83 | -0.7% | -3.7% | -6.1% | -5.0% | -2.8% | -2.3% |
| Feb 9 | TD Cowen | Maintains | Buy → Buy | — | $201.18 | $199.83 | -0.7% | -3.7% | -6.1% | -5.0% | -2.8% | -2.3% |
| Feb 9 | Piper Sandler | Maintains | Neutral → Neutral | — | $201.18 | $199.83 | -0.7% | -3.7% | -6.1% | -5.0% | -2.8% | -2.3% |
| Feb 9 | Truist | Maintains | Hold → Hold | — | $201.18 | $199.83 | -0.7% | -3.7% | -6.1% | -5.0% | -2.8% | -2.3% |
| Feb 9 | Citigroup | Maintains | Neutral → Neutral | — | $201.18 | $199.83 | -0.7% | -3.7% | -6.1% | -5.0% | -2.8% | -2.3% |
| Feb 9 | Wells Fargo | Maintains | Equal Weight → Equal Weight | — | $201.18 | $199.83 | -0.7% | -3.7% | -6.1% | -5.0% | -2.8% | -2.3% |
| Feb 9 | Canaccord Genuity | Maintains | Buy → Buy | — | $201.18 | $199.83 | -0.7% | -3.7% | -6.1% | -5.0% | -2.8% | -2.3% |
| Feb 9 | BMO Capital | Maintains | Market Perform → Market Perform | — | $201.18 | $199.83 | -0.7% | -3.7% | -6.1% | -5.0% | -2.8% | -2.3% |
| Feb 9 | Guggenheim | Maintains | Buy → Buy | — | $201.18 | $199.83 | -0.7% | -3.7% | -6.1% | -5.0% | -2.8% | -2.3% |
| Feb 9 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $201.18 | $199.83 | -0.7% | -3.7% | -6.1% | -5.0% | -2.8% | -2.3% |
| Jan 30 | Oppenheimer | Maintains | Outperform → Outperform | — | $176.18 | $177.09 | +0.5% | +2.1% | +1.7% | +0.3% | +5.3% | +5.2% |
| Jan 27 | Citigroup | Maintains | Neutral → Neutral | — | $173.12 | $173.02 | -0.1% | +0.6% | +1.0% | +1.8% | +3.9% | +3.4% |
| Jan 8 | Truist | Maintains | Hold → Hold | — | $186.91 | $187.02 | +0.1% | -0.5% | +0.4% | -0.7% | -4.6% | -9.4% |
| Jan 7 | Citigroup | Maintains | Neutral → Neutral | — | $182.61 | $181.70 | -0.5% | +2.4% | +1.9% | +2.7% | +1.7% | -2.4% |
| Dec 12 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $172.50 | $173.49 | +0.6% | +0.9% | +1.9% | -0.6% | -0.2% | -1.5% |
| Dec 10 | Wells Fargo | Maintains | Equal Weight → Equal Weight | — | $175.84 | $173.30 | -1.4% | +1.0% | -1.9% | -1.0% | -0.1% | -2.5% |
| Dec 10 | HSBC | Downgrade | Hold → Reduce | — | $175.84 | $173.30 | -1.4% | +1.0% | -1.9% | -1.0% | -0.1% | -2.5% |
| Nov 21 | Piper Sandler | Maintains | Neutral → Neutral | — | $168.18 | $168.54 | +0.2% | +4.2% | +5.1% | +8.2% | +8.2% | +8.3% |
| Nov 6 | Stifel | Upgrade | Hold → Buy | — | $153.43 | $155.76 | +1.5% | +2.2% | +1.4% | +1.8% | +4.0% | +5.2% |
| Nov 6 | Freedom Broker | Downgrade | Buy → Hold | — | $153.43 | $155.76 | +1.5% | +2.2% | +1.4% | +1.8% | +4.0% | +5.2% |
| Nov 3 | Bernstein | Maintains | Market Perform → Market Perform | — | $154.27 | $153.60 | -0.4% | -1.8% | -3.2% | -0.5% | +1.6% | +0.8% |
| Oct 31 | RBC Capital | Maintains | Outperform → Outperform | — | $149.61 | $147.99 | -1.1% | +3.1% | +1.2% | -0.2% | +2.6% | +4.8% |
| Oct 14 | Citigroup | Maintains | Neutral → Neutral | — | $144.69 | $144.09 | -0.4% | +0.4% | -0.7% | -1.7% | -1.2% | +1.3% |
| Oct 10 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $149.61 | $150.00 | +0.3% | -2.0% | -3.3% | -2.9% | -4.0% | -4.9% |
| Sep 24 | Needham | Maintains | Hold → Hold | — | $139.31 | $138.52 | -0.6% | -1.2% | -2.6% | -1.4% | -0.6% | +0.6% |
| Sep 4 | Needham | Maintains | Hold → Hold | — | $141.62 | $141.78 | +0.1% | -1.2% | -0.7% | -0.2% | +1.4% | +0.7% |
| Aug 14 | Piper Sandler | Maintains | Neutral → Neutral | — | $135.19 | $134.51 | -0.5% | -0.2% | +2.5% | +0.5% | +2.7% | +2.8% |
| Aug 1 | RBC Capital | Maintains | Outperform → Outperform | — | $128.00 | $128.96 | +0.8% | +3.1% | +3.3% | +3.8% | +1.0% | -0.2% |
| Aug 1 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $128.00 | $128.96 | +0.8% | +3.1% | +3.3% | +3.8% | +1.0% | -0.2% |
| Aug 1 | Citigroup | Maintains | Neutral → Neutral | — | $128.00 | $128.96 | +0.8% | +3.1% | +3.3% | +3.8% | +1.0% | -0.2% |
| Aug 1 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $128.00 | $128.96 | +0.8% | +3.1% | +3.3% | +3.8% | +1.0% | -0.2% |
No insider trades available.
8-K
Biogen Inc. -- 8-K Filing
Biogen demonstrated strong financial momentum with Non-GAAP EPS growing 31% year-over-year and LEQEMBI sales surging 74%, signaling successful commercial execution across its neurology portfolio.
Apr 29
8-K
Unknown — 8-K Filing
This standard safe harbor language indicates Biogen is protecting itself from litigation over forward-looking statements, suggesting management made optimistic projections investors should scrutinize carefully for accuracy.
Apr 6
8-K
Unknown — 8-K Filing
Biogen is acquiring Apellis for an upfront payment plus contingent value rights, signaling aggressive expansion into complement-driven therapies and providing Apellis shareholders a defined exit with potential earn-out upside.
Mar 31
8-K
Unknown — 8-K Filing
I need more substantive information from the 8-K filing to provide meaningful analysis. The summary provided only contains technical metadata about the document format rather than actual business content or events that would impact BIIB's stock.
Could you provide the actual filing details, such as material events, executive changes, financial updates, or strategic announcements?
Mar 11
8-K
Biogen Inc. -- 8-K Filing
I cannot provide a meaningful analysis of this filing as the summary contains only technical XBRL metadata and schema references without substantive business information about Biogen's actions or events.
Feb 11
8-K
Biogen Inc. -- 8-K Filing
Biogen's SKYCLARYS generated $78 million in global sales with 30% patient growth in Q4 2025, signaling strong commercial traction for this rare disease treatment.
Feb 6
Data updated apr 24, 2026 9:37pm
· Source: massive.com